O le InnoCare Pharma, o se kamupani taʻutaʻua biopharmaceutical, na faʻasalalau i aso nei o le tagata muamua na faʻamaʻiina i le Vaega II faʻataʻitaʻiga faʻataʻitaʻiga o lona Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib mo togafitiga o le thrombocytopenia puipuia muamua (ITP) i Saina.
Primary immune thrombocytopenia (ITP), e taʻua foʻi o le idiopathic thrombocytopenic purpura, o se maʻi faʻalavelave faʻafuaseʻi na maua e faʻaalia i le faʻaitiitia o le aofaʻi o platelet toto, e mafua ai le faʻateleina o le lamatiaga o le toto ma le toto [i]. O le mafuaʻaga autu o le ITP o le leiloa o le faʻapalepale puipuia i platelet auto-antigens. O lenei le faapalepale puipuia e taitai atu ai i le faateleina o le faaleagaina o platelet ma faaitiitia le gaosiga o platelet mai megakaryocytes e autoantibodies ma cytotoxic T lymphocytes.
E naʻo le 70% o tagata gasegase e tali atu i togafitiga muamua, o nisi o gasegase o loʻo tumau pea pe toe faʻafoʻi pe a maeʻa togafitiga tuʻufaʻatasia, o lea e manaʻomia ai le suʻesuʻeina o faʻasologa fou o togafitiga. O le fa'asaina o le BTK e mafai ona fa'aitiitia le fa'aleagaina o platelet e ala i le taofia o le fa'agaioiina o sela B ma le gaosiga o le autoantibody.
Ole a'afiaga ole ITP ile tausaga i tagata matutua e tusa ma le 2-10 mataupu fou ile 100,000 tagata[ii],[iii]. O tagata matutua i luga atu o le 60 tausaga le matutua e maualuga le lamatiaga o le ITP, ma o tamaitai e fananau mai e maualuga atu le lamatiaga nai lo alii o le vaitausaga tutusa.
O Dr. Jasmine Cui, o le faʻavae faʻavae, Taʻitaʻifono ma le Pule Sili o InnoCare na fai mai, "E leai se BTK inhibitor ua faʻatagaina mo togafitiga o tagata mamaʻi i le ITP i le lalolagi. O le BTK o se kinase autu i le B cell receptor signaling pathway, lea e taua mo le faʻagaoioia o B lymphocytes, macrophages ma isi sela puipuia faʻapea foʻi ma le gaosiga o antibodies i le pathological process o ITP. Orelabrutinib e maualuga le filifilia ma le saogalemu, lea e faʻamoemoe e aumaia ai togafitiga fou i tagata mamaʻi ITP.
OA MEA E AVEA MAI LENEI TUSI:
- BTK is a key kinase in the B cell receptor signaling pathway, which is essential for the activation of B lymphocytes, macrophages and other immune cells as well as the production of antibodies in the pathological process of ITP.
- Primary immune thrombocytopenia (ITP), also referred to as idiopathic thrombocytopenic purpura, is an acquired immune mediated disorder characterized by a decrease in peripheral blood platelet counts, resulting in an increased risk of bruising and bleeding[i].
- Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, “No BTK inhibitor has been approved for the treatment of patients with ITP in the world.
